Kura Oncology Inc (OQ:KURA)

Mar 06, 2024 07:30 am ET
Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell Carcinoma
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced dosing of the first patient with KO-2806, the Company’s...
Mar 01, 2024 05:00 pm ET
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on March 1, 2024, the Compensation Committee...
Feb 27, 2024 04:01 pm ET
Kura Oncology Reports Fourth Quarter and Full Year 2023 Financial Results
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today reported fourth quarter and full year 2023 financial results and provided a...
Feb 26, 2024 07:30 am ET
Kura Oncology Doses First Patient in KOMET-008 Trial of Ziftomenib in Combination with Standards of Care, Including FLT3 Inhibitor, in Acute Myeloid Leukemia
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that the first patient has been dosed in KOMET-008, the Company’s...
Feb 22, 2024 07:30 am ET
Kura Oncology to Participate in Three Upcoming Investor Conferences
Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive...
Feb 20, 2024 07:30 am ET
Kura Oncology to Report Fourth Quarter and Full Year 2023 Financial Results
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report fourth quarter and full year 2023 financial...
Feb 02, 2024 07:30 am ET
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on February 1, 2024, the Compensation...
Jan 30, 2024 08:31 am ET
Thinking about buying stock in Kura Oncology, Akebia Therapeutics, American Airlines, Evaxion Biotech, or Minim?
NEW YORK, Jan. 30, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for KURA, AKBA, AAL, EVAX, and MINM.
Jan 30, 2024 07:00 am ET
Kura Oncology Reports Positive Preliminary Ziftomenib Combination Data in Acute Myeloid Leukemia
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today reported preliminary clinical data from the first 20 patients in KOMET-007,...
Jan 24, 2024 08:31 am ET
Thinking about buying stock in Kura Oncology, UiPath, C3.ai, Crowdstrike, or RedHill Biopharma?
NEW YORK, Jan. 24, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for KURA, PATH, AI, CRWD, and RDHL.
Jan 24, 2024 07:00 am ET
Kura Oncology Announces Oversubscribed $150 Million Private Placement
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it has agreed to sell 1,376,813 shares of its common stock at...
Dec 08, 2023 07:30 am ET
Kura Oncology’s Menin Inhibitor Ziftomenib Selected for The Leukemia & Lymphoma Society’s Pediatric Acute Leukemia (PedAL) Master Clinical Trial
Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, and The Leukemia & Lymphoma Society (LLS), the largest private funder of blood...
Nov 28, 2023 07:30 am ET
Kura Oncology to Participate in the JMP Securities Hematology and Oncology Summit
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive...
Nov 02, 2023 04:01 pm ET
Kura Oncology Reports Third Quarter 2023 Financial Results
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today reported third quarter 2023 financial results and provided a corporate...
Nov 02, 2023 07:30 am ET
Kura Oncology and Mirati Therapeutics Enter into Clinical Collaboration and Supply Agreement to Evaluate KO-2806 and Adagrasib in KRASᴳ¹²ᶜ-Mutated NSCLC
Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, and Mirati Therapeutics, Inc. (NASDAQ: MRTX), a commercial-stage targeted oncology...
Oct 30, 2023 07:30 am ET
Kura Oncology to Participate in Three Upcoming Investor Conferences
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive...
Oct 26, 2023 04:05 pm ET
Kura Oncology to Report Third Quarter 2023 Financial Results
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report third quarter 2023 financial results after the...
Oct 19, 2023 07:30 am ET
Kura Oncology Announces First Patient Dosed in FIT-001 Trial of Next-Generation Farnesyl Transferase Inhibitor KO-2806
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that the first patient has been dosed in the FIT-001 Phase 1...
Oct 17, 2023 04:05 pm ET
Kura Oncology Announces Positive Results from Registration-Directed Study of Tipifarnib in Patients with HRAS Mutant HNSCC
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced results from its registration-directed AIM-HN study of tipifarnib...
Oct 04, 2023 07:30 am ET
Kura Oncology Announces Three Presentations at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that three abstracts have been accepted for poster presentation at...
Sep 28, 2023 07:30 am ET
Kura Oncology Reports Preclinical Data Showing Ability of KO-2806 to Enhance Antitumor Activity of KRASᴳ¹²ᶜ Inhibitors in Non-Small Cell Lung Cancer
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today reported preclinical data supporting the development of its next-generation...
Sep 19, 2023 07:30 am ET
Kura Oncology to Participate in Cantor Global Healthcare Conference 2023
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the upcoming Cantor Global Healthcare...
Aug 14, 2023 07:30 am ET
Kura Oncology Appoints Brian Powl as Chief Commercial Officer
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the appointment of Brian Powl as Chief Commercial Officer. Mr....
Aug 03, 2023 04:05 pm ET
Kura Oncology Reports Second Quarter 2023 Financial Results
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today reported second quarter 2023 financial results and provided a corporate...
Jul 27, 2023 07:30 am ET
Kura Oncology to Report Second Quarter 2023 Financial Results
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report second quarter 2023 financial results after...
Jun 14, 2023 07:00 am ET
Kura Oncology Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the pricing of an underwritten public offering of common stock and...
Jun 13, 2023 04:01 pm ET
Kura Oncology Announces Commencement of Public Offering of Common Stock and Pre-Funded Warrants
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it has commenced an underwritten public offering, subject to...
Jun 11, 2023 03:45 am ET
Kura Oncology Presents Late-Breaking Clinical Data for Menin Inhibitor Ziftomenib at 2023 European Hematology Association (EHA) Congress
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced updated clinical data from KOMET-001, a Phase 1/2 clinical trial...
May 30, 2023 07:30 am ET
Kura Oncology Announces Late-Breaking Abstract Accepted for Oral Presentation at the 2023 European Hematology Association (EHA) Congress
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that a late-breaking abstract with updated data from the Phase 1...
May 23, 2023 07:30 am ET
Kura Oncology to Participate in Two Upcoming Investor Conferences
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive...
May 10, 2023 04:03 pm ET
Kura Oncology Reports First Quarter 2023 Financial Results
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today reported first quarter 2023 financial results and provided a corporate...
May 09, 2023 07:30 am ET
Kura Oncology to Participate in JMP Securities Life Sciences Conference
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the JMP Securities Life Sciences Conference...
May 03, 2023 07:30 am ET
Kura Oncology to Report First Quarter 2023 Financial Results
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report first quarter 2023 financial results after the...
Apr 18, 2023 07:30 am ET
Kura Oncology to Participate in Stifel Targeted Oncology Days
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in Stifel 2023 Targeted Oncology Days. Troy...
Apr 17, 2023 07:30 am ET
Kura Oncology Reports Preclinical Data Highlighting Synergistic Activity of Farnesyl Transferase Inhibitor in Combination with Targeted Therapies
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today reported preclinical data supporting the potential use of farnesyl...
Mar 14, 2023 05:32 pm ET
Kura Oncology Announces Acceptance of Two Abstracts for Presentation at AACR Annual Meeting
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that two abstracts have been accepted for presentation at the...
Mar 01, 2023 07:30 am ET
Kura Oncology to Participate in Upcoming Investor Conferences
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive...
Feb 23, 2023 04:03 pm ET
Kura Oncology Reports Fourth Quarter and Full Year 2022 Financial Results
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today reported fourth quarter and full year 2022 financial results and provided a...
Feb 16, 2023 07:30 am ET
Kura Oncology to Report Fourth Quarter and Full Year 2022 Financial Results
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report fourth quarter and full year 2022 financial...
Feb 09, 2023 07:30 am ET
Kura Oncology Announces First Patients Dosed in Phase 2 Registration-Directed Trial of Ziftomenib in NPM1-Mutant Acute Myeloid Leukemia
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that the first patients have been dosed in its KOMET-001 Phase 2...
Feb 07, 2023 07:30 am ET
Kura Oncology to Participate in SVB Securities Global Biopharma Conference
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the virtual SVB Securities Global Biopharma...
Jan 24, 2023 07:30 am ET
Kura Oncology Announces FDA Clearance of IND Application for KO-2806, a Next-Generation Farnesyl Transferase Inhibitor
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the clearance by the U.S. Food and Drug Administration (FDA) of...
Dec 10, 2022 10:30 am ET
Kura Oncology Presents Updated Clinical Data from KOMET-001 Trial of Menin Inhibitor Ziftomenib at American Society of Hematology Annual Meeting
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced updated clinical data from KOMET-001, a Phase 1/2 trial of the...
Dec 01, 2022 07:30 am ET
Kura Oncology to Host Investor Event on December 10, 2022
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will host an investor event featuring members of the Kura...
Nov 22, 2022 07:30 am ET
Kura Oncology to Participate in Two Upcoming Investor Conferences
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive...
Nov 03, 2022 09:00 am ET
Kura Oncology Announces Four Abstracts Accepted for Presentation at ASH Annual Meeting
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that four abstracts highlighting ziftomenib, the Company’s potent...
Nov 03, 2022 07:30 am ET
Kura Oncology Reports Third Quarter 2022 Financial Results
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today reported third quarter 2022 financial results and provided a corporate...
Nov 03, 2022 07:00 am ET
Kura Oncology Announces Financing Transactions with Bristol Myers Squibb and Hercules Capital, Providing Access to up to $150 Million
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced a $25 million equity investment from Bristol Myers Squibb (NYSE:...
Nov 02, 2022 07:30 am ET
Kura Oncology to Participate in Two Upcoming Investor Conferences
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive...
Oct 27, 2022 07:30 am ET
Kura Oncology to Report Third Quarter 2022 Financial Results  
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report third quarter 2022 financial results before...
Oct 26, 2022 07:30 am ET
Kura Oncology Reports Preliminary Proof of Mechanism in Phase 1/2 Clinical Trial of Tipifarnib Plus Alpelisib in Head and Neck Squamous Cell Carcinoma
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today reported proof of mechanism in KURRENT-HN, the Company’s Phase 1/2 clinical...
Sep 01, 2022 07:30 am ET
Kura Oncology to Participate in H.C. Wainwright Global Investment Conference
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive...
Aug 03, 2022 04:03 pm ET
Kura Oncology Reports Second Quarter 2022 Financial Results
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today reported second quarter 2022 financial results and provided a corporate...
Aug 02, 2022 07:30 am ET
Kura Oncology to Participate in Wedbush PacGrow Healthcare Virtual Conference
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the Wedbush PacGrow Healthcare Virtual...
Jul 27, 2022 07:30 am ET
Kura Oncology to Report Second Quarter 2022 Financial Results
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report second quarter 2022 financial results after...
Jul 13, 2022 10:55 am ET
Thinking about buying stock in Humanigen, Endo International, Kura Oncology, Delta Air Lines, or Clovis Oncology?
NEW YORK, July 13, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for HGEN, ENDP, KURA, DAL, and CLVS.
Jun 23, 2022 07:00 am ET
Viridian Therapeutics Appoints Carrie Melvin as Chief Operating Officer
Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies, today announced the appointment of Carrie Melvin as Chief Operating Officer,...
Jun 03, 2022 08:00 am ET
Celularity Appoints Industry Leader Diane Parks to its Board of Directors
Celularity Inc. (Nasdaq: CELU) (“Celularity”), a clinical-stage biotechnology company developing placental-derived off-the-shelf allogeneic cell therapies, today announced the appointment of Diane Parks to its Board of Directors. Ms. Parks, an...
May 26, 2022 07:30 am ET
Kura Oncology to Participate in Three Upcoming Investor Conferences
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive...
May 04, 2022 04:05 pm ET
Kura Oncology Reports First Quarter 2022 Financial Results
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today reported first quarter 2022 financial results and provided a corporate...
Apr 27, 2022 07:30 am ET
Kura Oncology to Report First Quarter 2022 Financial Results
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report first quarter 2022 financial results after the...
Apr 08, 2022 01:00 pm ET
Kura Oncology Reports Preclinical Data Supporting Use of Tipifarnib to Prevent Emergence of Resistance to Osimertinib in Non-Small Cell Lung Cancer
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today reported preclinical data supporting the potential of its farnesyl...
Mar 08, 2022 05:30 pm ET
Kura Oncology Announces Multiple Abstracts Accepted for Presentation at AACR Annual Meeting
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that four abstracts have been accepted for presentation at the...
Feb 28, 2022 07:30 am ET
Kura Oncology to Participate in Two Upcoming Investor Conferences
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive...
Feb 24, 2022 04:03 pm ET
Kura Oncology Reports Fourth Quarter and Full Year 2021 Financial Results
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today reported fourth quarter and full year 2021 financial results and provided a...
Feb 17, 2022 07:30 am ET
Kura Oncology to Report Fourth Quarter and Full Year 2021 Financial Results
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report fourth quarter and full year 2021 financial...
Feb 10, 2022 07:30 am ET
Kura Oncology to Participate in SVB Leerink Global Healthcare Conference
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the 11th Annual SVB Leerink Global Healthcare...
Feb 01, 2022 04:01 pm ET
Kura Oncology Expands Leadership Team with Key Promotions
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the expansion of its leadership team with three promotions: Mollie...
Jan 20, 2022 04:01 pm ET
Kura Oncology Receives FDA Authorization to Proceed with Phase 1b Study of KO-539 in Acute Myeloid Leukemia
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has lifted the...
Dec 16, 2021 09:16 am ET
Kura Oncology Doses First Patient in Phase 1/2 Clinical Trial of Tipifarnib in Combination with Alpelisib in Head and Neck Squamous Cell Carcinoma
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced dose administration for the first patient in KURRENT, the...
Dec 13, 2021 10:43 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Kura Oncology, Inc. - KURA
NEW YORK, Dec. 13, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Kura Oncology, Inc. ("Kura" or the "Company") (NASDAQ: KURA). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Dec 13, 2021 10:30 am ET
Kura Oncology Reports Final Results from Phase 2 Study of Tipifarnib in T-Cell Lymphoma
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced final results from a Phase 2 study of tipifarnib as a monotherapy...
Dec 13, 2021 07:00 am ET
Kura Oncology Reports Preclinical Data Highlighting Synergistic Activity of Menin Inhibitor KO-539 in Combination with Venetoclax
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the presentation of new preclinical data for KO-539, the Company’s...
Nov 30, 2021 07:41 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Kura Oncology, Inc. - KURA
Pomerantz LLP is investigating claims on behalf of investors of Kura Oncology, Inc. (“Kura” or the “Company”) (NASDAQ: KURA). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The...
Nov 25, 2021 10:34 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Kura Oncology, Inc. - KURA
NEW YORK, Nov. 25, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Kura Oncology, Inc. ("Kura" or the "Company") (NASDAQ: KURA).  Such investors are advised to contact Robert S. Willoughby at  [email protected] or 888-476-6529, ext. 7980.
Nov 24, 2021 08:42 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Kura Oncology, Inc. - KURA
Pomerantz LLP is investigating claims on behalf of investors of Kura Oncology, Inc. (“Kura” or the “Company”) (NASDAQ: KURA). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The...
Nov 24, 2021 06:45 am ET
Kura Oncology Provides Update on Phase 1b Study of KO-539 in Acute Myeloid Leukemia
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has placed the...
Nov 23, 2021 07:30 am ET
Kura Oncology to Participate in Two Upcoming Investor Conferences
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive...
Nov 04, 2021 04:05 pm ET
Kura Oncology Reports Third Quarter 2021 Financial Results
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today reported third quarter 2021 financial results and provided a corporate...
Nov 02, 2021 07:30 am ET
Kura Oncology to Participate in Credit Suisse Healthcare Conference
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the Credit Suisse 30th Annual Healthcare...
Oct 28, 2021 07:30 am ET
Kura Oncology to Report Third Quarter 2021 Financial Results
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report third quarter 2021 financial results after the...
Oct 18, 2021 07:30 am ET
Kura Oncology Appoints Teresa Bair as Chief Legal Officer
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the appointment of Teresa Bair as Chief Legal Officer and...
Sep 07, 2021 07:30 am ET
Kura Oncology to Participate in Two Upcoming Investor Conferences
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive...
Aug 05, 2021 04:05 pm ET
Kura Oncology Reports Second Quarter 2021 Financial Results
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today reported second quarter 2021 financial results and provided a corporate...
Aug 04, 2021 07:30 am ET
Kura Oncology to Participate in Wedbush PacGrow Healthcare Virtual Conference
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the Wedbush PacGrow Healthcare Virtual...
Jul 29, 2021 04:05 pm ET
Kura Oncology to Report Second Quarter 2021 Financial Results
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report second quarter 2021 financial results after...
Jul 29, 2021 07:30 am ET
Kura Oncology Appoints Helen Collins, M.D. to Board of Directors
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the appointment of industry veteran Helen Collins, M.D., to its...
Jul 06, 2021 07:30 am ET
Kura Oncology Announces Clinical Collaboration to Evaluate Tipifarnib in Combination with Alpelisib in Head and Neck Squamous Cell Carcinoma
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced a clinical collaboration with Novartis to evaluate the combination...
Jun 24, 2021 08:30 am ET
Kura Oncology Doses First Patient in Phase 1b Expansion Cohorts with Menin Inhibitor KO-539
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that the first patient has been dosed in the Phase 1b portion of...
Jun 10, 2021 07:30 am ET
Kura Oncology to Participate in JMP Securities Life Sciences Conference
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the JMP Securities Life Sciences Conference....
Jun 04, 2021 07:30 am ET
Kura Oncology Appoints Carol Schafer to Board of Directors
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the appointment of Wall Street veteran Carol Schafer to its board...
May 13, 2021 07:30 am ET
Kura Oncology to Participate in Cowen Virtual Oncology Innovation Summit
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the Cowen 2nd Annual Virtual Oncology...
May 06, 2021 04:04 pm ET
Kura Oncology Reports First Quarter 2021 Financial Results
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today reported first quarter 2021 financial results and provided a corporate...
Apr 29, 2021 07:30 am ET
Kura Oncology to Report First Quarter 2021 Financial Results
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report first quarter 2021 financial results after the...
Mar 22, 2021 04:08 pm ET
Kura Oncology Announces Publication of Tipifarnib Phase 2 Data in Journal of Clinical Oncology
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the publication of results from its RUN-HN study, a Phase 2...
Feb 24, 2021 07:20 am ET
Kura Oncology Reports Fourth Quarter and Full Year 2020 Financial Results
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today reported fourth quarter and full year 2020 financial results and provided a...
Feb 24, 2021 07:00 am ET
Kura Oncology Receives FDA Breakthrough Therapy Designation for Tipifarnib in Head and Neck Squamous Cell Carcinoma
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that its investigational drug, tipifarnib, has been granted...
Feb 18, 2021 07:30 am ET
Kura Oncology to Participate in Four Upcoming Investor Conferences
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive...
Feb 17, 2021 07:30 am ET
Kura Oncology to Report Fourth Quarter and Full Year 2020 Financial Results
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report fourth quarter and full year 2020 financial...
Jan 07, 2021 07:30 am ET
Kura Oncology to Participate in H.C. Wainwright BioConnect 2021 Conference
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation at the H.C. Wainwright BioConnect 2021...
Jan 06, 2021 07:30 am ET
Kura Oncology to Present at J.P. Morgan Healthcare Conference
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation at the 39th Annual J.P. Morgan Healthcare...
Dec 11, 2020 04:05 pm ET
Kura Oncology Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the closing of its previously announced underwritten public...
Dec 10, 2020 07:30 am ET
Kura Oncology to Participate in the JMP Securities Hematology Summit
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the JMP Securities Hematology Summit. Troy...
Dec 08, 2020 08:21 pm ET
Kura Oncology Announces Pricing of $300 Million Public Offering of Common Stock
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the pricing of an underwritten public offering of 8,110,000 shares...
Dec 07, 2020 04:01 pm ET
Kura Oncology Announces Commencement of Public Offering of Common Stock
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it has commenced an underwritten public offering, subject to...
Dec 07, 2020 08:31 am ET
Thinking about buying stock in Affimed NV, Kura Oncology, Matinas BioPharma, Uranium Energy, or Senseonics Holdings?
NEW YORK, Dec. 7, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AFMD, KURA, MTNB, UEC, and SENS.
Dec 05, 2020 12:30 pm ET
Kura Oncology Presents First Clinical Data for Menin Inhibitor KO-539 at American Society of Hematology Annual Meeting
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced preliminary clinical data from KOMET-001, an ongoing Phase 1/2A clinical...
Nov 24, 2020 07:30 am ET
Kura Oncology to Host Virtual Investor Event on December 5, 2020
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will be hosting a virtual investor event to provide a...
Nov 05, 2020 07:30 am ET
Kura Oncology Reports Third Quarter 2020 Financial Results
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today reported third quarter 2020 financial results and provided a corporate...
Nov 04, 2020 07:30 am ET
Kura Oncology to Participate in Three Upcoming Investor Conferences
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that management is scheduled to participate in three upcoming...
Oct 29, 2020 07:30 am ET
Kura Oncology to Report Third Quarter 2020 Financial Results
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that it will report third quarter 2020 financial results before the open...
Oct 26, 2020 07:30 am ET
Kura Oncology Reports Preclinical Results Showing Antitumor Activity of Tipifarnib in Combination with PI3Kα Inhibitor in Head and Neck Squamous Cell Carcinoma
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, reported new preclinical data demonstrating the Company’s late-stage drug candidate,...
Oct 07, 2020 07:30 am ET
Kura Oncology Announces Preliminary Data for Menin Inhibitor KO-539 Accepted for Oral Presentation at ASH
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that an abstract reporting preliminary data from KOMET-001, an ongoing...
Sep 08, 2020 07:30 am ET
Kura Oncology to Participate in Two Upcoming Investor Conferences
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive...
Aug 25, 2020 07:30 am ET
Kura Oncology Appoints Dr. Stephen Dale as Chief Medical Officer
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced the appointment of Stephen Dale, M.D., as Chief Medical Officer. Dr. Dale...
Aug 06, 2020 04:05 pm ET
Kura Oncology Reports Second Quarter 2020 Financial Results
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today reported second quarter 2020 financial results and provided a corporate...
Aug 04, 2020 07:30 am ET
Kura Oncology to Present at Wedbush PacGrow Healthcare Virtual Conference
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation at the 2020 Wedbush PacGrow Healthcare Virtual...
Jul 30, 2020 07:30 am ET
Kura Oncology to Report Second Quarter 2020 Financial Results
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that it will report second quarter 2020 financial results after the close...
Jun 11, 2020 07:30 am ET
Kura Oncology to Participate in JMP Securities Hematology & Oncology Forum
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the JMP Securities Hematology & Oncology...
May 29, 2020 08:00 am ET
Kura Oncology Reports Overall Survival Data from Phase 2 Trial of Tipifarnib in HRAS Mutant Head and Neck Squamous Cell Carcinoma
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced updated clinical outcome data from its RUN-HN study, a Phase 2...
May 13, 2020 05:00 pm ET
Kura Oncology Announces Three Abstracts Accepted for Presentation at ASCO20 Virtual Scientific Program
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that three abstracts highlighting its drug candidate tipifarnib...
May 08, 2020 04:03 pm ET
Kura Oncology Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the closing of its previously announced underwritten public...
May 07, 2020 07:30 am ET
Kura Oncology to Present at BofA Securities Virtual Health Care Conference 2020
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation at the BofA Securities Virtual Healthcare...
May 06, 2020 09:00 am ET
Kura Oncology Announces Pricing of $125 Million Public Offering of Common Stock
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the pricing of an underwritten public offering of 9,100,000 shares...
May 05, 2020 04:01 pm ET
Kura Oncology Announces Commencement of Public Offering of Common Stock
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it has commenced an underwritten public offering, subject to...
May 04, 2020 04:05 pm ET
Kura Oncology Reports First Quarter 2020 Financial Results
rearranged AML – – Three abstracts accepted for presentation at ASCO, including mature data from Phase 2 study of tipifarnib in HRAS mutant HNSCC – – $216.9 million in cash, cash equivalents and investments provide strong cash position and...
Apr 29, 2020 09:31 am ET
Thinking about buying stock in Kura Oncology, WW International, Royal Caribbean Cruises, FuelCell Energy, or resTORbio?
NEW YORK, April 29, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for KURA, WW, RCL, FCEL, and TORC.
Apr 29, 2020 07:30 am ET
Kura Oncology to Report First Quarter 2020 Financial Results
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that it will report first quarter 2020 financial results after the close...
Mar 03, 2020 07:30 am ET
Kura Oncology Receives Fast Track Designation for Tipifarnib in T-Cell Lymphomas
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track...
Feb 25, 2020 04:03 pm ET
Kura Oncology Reports Fourth Quarter and Full Year 2019 Financial Results
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today reported fourth quarter and full year 2019 financial results and provided a...
Feb 19, 2020 04:05 pm ET
Kura Oncology to Participate in Three Upcoming Investor Conferences
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is...
Feb 18, 2020 04:05 pm ET
Kura Oncology to Report Fourth Quarter and Full Year 2019 Financial Results
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that it will report fourth quarter and full year 2019 financial results...
Jan 23, 2020 04:05 pm ET
Kura Oncology Announces Transition of Chief Medical Officer
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that Antonio Gualberto, M.D., Ph.D., will step down as Head of Development...
Jan 09, 2020 07:30 am ET
Kura Oncology to Present at J.P. Morgan Healthcare Conference
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced its participation at the 38th Annual J.P. Morgan Healthcare Conference....
Jan 06, 2020 07:30 am ET
Kura Oncology Appoints Kirsten Flowers as Chief Commercial Officer
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced the appointment of Kirsten Flowers as Chief Commercial Officer. Ms....
Dec 16, 2019 07:30 am ET
Kura Oncology Receives Fast Track Designation for Tipifarnib in HRAS Mutant HNSCC and Provides Enrollment Guidance for AIM-HN Trial
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track...
Dec 08, 2019 12:00 pm ET
Kura Oncology Reports Clinical and Regulatory Updates for Tipifarnib in Angioimmunoblastic T-Cell Lymphoma
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced clinical and regulatory updates for its lead drug candidate, tipifarnib,...
Nov 26, 2019 07:30 am ET
Kura Oncology to Participate in Piper Jaffray Healthcare Conference
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive...
Nov 12, 2019 07:30 am ET
Kura Oncology to Present at Stifel Healthcare Conference
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive...
Nov 06, 2019 09:06 am ET
Kura Oncology Announces Upcoming Presentation at ASH Annual Meeting
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that an abstract related to the Company’s lead drug candidate, tipifarnib,...
Nov 05, 2019 04:05 pm ET
Kura Oncology Reports Third Quarter 2019 Financial Results and Provides Corporate Update
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today reported third quarter 2019 financial results and provided a corporate...
Nov 04, 2019 07:30 am ET
Kura Oncology Appoints James Basta as Chief Legal Officer
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced the appointment of James Basta as Chief Legal Officer and Corporate...
Oct 30, 2019 07:30 am ET
Kura Oncology to Report Third Quarter 2019 Financial Results
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that it will report third quarter 2019 financial results after the close...
Oct 29, 2019 11:50 am ET
Kura Oncology Reports Durable Anti-Tumor Activity in Phase 2 Trial of Tipifarnib in HRAS Mutant Head and Neck Cancer
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today reported updated data from a Phase 2 clinical trial of its lead drug candidate,...
Oct 23, 2019 04:05 pm ET
Kura Oncology Data Selected for Oral Presentation at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that an abstract containing data from the Company’s Phase 2 clinical trial...
Oct 16, 2019 04:30 pm ET
Kura Oncology Announces Upcoming Presentation at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that an abstract related to the Company’s Phase 2 clinical trial of...
Oct 15, 2019 07:30 am ET
Kura Oncology Expands Board of Directors with Appointment of Diane Parks
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced the appointment of veteran commercial executive Diane Parks to its board...
Sep 16, 2019 07:30 am ET
Kura Oncology Doses First Patient in Phase 1 Clinical Trial of Menin-MLL Inhibitor KO-539 in Acute Myeloid Leukemia
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that the first patient has been dosed in a Phase 1 clinical trial of...
Sep 03, 2019 07:30 am ET
Kura Oncology Announces Positive Phase 2 Trial of Tipifarnib in HRAS Mutant Urothelial Carcinoma
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced positive topline results from an investigator-sponsored Phase 2 trial of its lead drug...
Aug 29, 2019 07:30 am ET
Kura Oncology to Participate in Two Upcoming Investor Conferences
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is...
Aug 12, 2019 04:05 pm ET
Kura Oncology Announces Appointment of Kathleen Ford as Chief Operating Officer
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced the appointment of Kathleen Ford as Chief Operating Officer, effective...
Aug 07, 2019 07:30 am ET
Kura Oncology to Present at Wedbush PacGrow Healthcare Conference
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive...
Aug 01, 2019 04:05 pm ET
Kura Oncology Reports Second Quarter 2019 Financial Results and Provides Corporate Update
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today reported second quarter 2019 financial results and provided a corporate...
Jul 25, 2019 07:30 am ET
Kura Oncology to Report Second Quarter 2019 Financial Results
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that it will report second quarter 2019 financial results after the close...
Jul 24, 2019 07:30 am ET
Kura Oncology’s Menin-MLL Inhibitor KO-539 Receives Orphan Drug Designation from FDA for Treatment of Acute Myeloid Leukemia
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to...
Jul 11, 2019 07:30 am ET
Kura Oncology Expands Protection for Tipifarnib with New U.S. and European Patents
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that the U.S. Patent and Trademark Office (USPTO) has issued and the...
Jun 21, 2019 04:30 pm ET
Kura Oncology Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced the closing of its previously announced underwritten public offering of common stock,...
Jun 18, 2019 11:31 pm ET
Kura Oncology Announces Pricing of $100 Million Public Offering of Common Stock
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced the pricing of an underwritten public offering of 5,900,000 shares of its common stock at...
Jun 18, 2019 04:01 pm ET
Kura Oncology Announces Commencement of Public Offering of Common Stock
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that it has commenced an underwritten public offering, subject to market and other...
Jun 14, 2019 07:00 am ET
Kura Oncology Announces Positive Phase 2 Trial of Tipifarnib in Peripheral T-Cell Lymphoma
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced updated interim data from the ongoing Phase 2 clinical trial of its lead drug candidate,...
May 08, 2019 08:00 am ET
Kura Oncology to Present at Bank of America Merrill Lynch Health Care Conference
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to...
May 07, 2019 04:05 pm ET
Kura Oncology Reports First Quarter 2019 Financial Results and Highlights Upcoming Milestones
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today reported first quarter 2019 financial results and highlighted upcoming...
Apr 30, 2019 07:30 am ET
Kura Oncology to Report First Quarter 2019 Financial Results
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that it will report first quarter 2019 financial results after the close of U.S....
Apr 02, 2019 04:04 pm ET
Kura Oncology Identifies Farnesylated Proteins Associated with CXCL12 Expression, Potential Biomarker of Clinical Benefit from Tipifarnib in Lymphoma Indications
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, reported new findings regarding the mechanism of action of the Company’s lead drug candidate tipifarnib...
Mar 29, 2019 07:10 am ET
Detailed Research: Economic Perspectives on Five Below, INVESCO MORTGAGE CAPITAL INC, Amicus Therapeutics, Akamai Technologies, Kura Oncology, and Columbus McKinnon — What Drives Growth in Today's Com
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Five Below, Inc. (NASDAQ:FIVE), INVESCO MORTGAGE CAPITAL INC (NYSE:IVR),...
Mar 06, 2019 07:30 am ET
Kura Oncology to Participate in Two Upcoming Investor Conferences
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to...
Mar 05, 2019 04:03 pm ET
Kura Oncology Reports Fourth Quarter and Full Year 2018 Financial Results
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today reported fourth quarter and full year 2018 financial results and provided a...
Mar 05, 2019 07:30 am ET
Kura Oncology Announces FDA Clearance of Investigational New Drug Application for Menin-MLL Inhibitor KO-539
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s...
Feb 26, 2019 07:30 am ET
Kura Oncology to Report Fourth Quarter and Full Year 2018 Financial Results
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that it will report fourth quarter and full year 2018 financial results after the close...
Feb 20, 2019 07:30 am ET
Kura Oncology to Present at SVB Leerink Global Healthcare Conference
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to...
Feb 19, 2019 07:40 am ET
Detailed Research: Economic Perspectives on Tesla, Kura Oncology, ASML Holding N.V, Applied Industrial Technologies, Raven Industries, and Intra-Cellular Therapies — What Drives Growth in Today's Comp
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Tesla, Inc. (NASDAQ:TSLA), Kura Oncology, Inc. (NASDAQ:KURA), ASML Holding...
Jan 18, 2019 10:00 am ET
Kura Oncology Reports Clinical Activity of Tipifarnib in Subsets of Pancreatic Cancer Associated with High CXCL12 Expression
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, reported new findings identifying a potential association between CXCL12 expression and clinical benefit...
Jan 03, 2019 07:30 am ET
Kura Oncology to Present at J.P. Morgan Healthcare Conference
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced its participation at the 37th Annual J.P. Morgan Healthcare Conference. Troy Wilson,...
Dec 02, 2018 12:00 pm ET
Kura Oncology Announces Proof of Concept in Angioimmunoblastic T-Cell Lymphoma, Validation of CXCL12 as a Therapeutic Target of Tipifarnib in Peripheral T-Cell Lymphoma
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, reported preliminary data in angioimmunoblastic T-cell lymphoma (AITL) and CXCL12+ peripheral T-cell...
Nov 30, 2018 07:50 am ET
Report: Exploring Fundamental Drivers Behind J.B. Hunt Transport Services, Kura Oncology, National Beverage, Benefitfocus, PTC Therapeutics, and Walgreens Boots Alliance — New Horizons, Emerging Trend
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of J.B. Hunt Transport Services, Inc. (NASDAQ:JBHT), Kura Oncology, Inc....
Nov 28, 2018 07:30 am ET
Kura Oncology Announces New Patent for Tipifarnib in Angioimmunoblastic T-Cell Lymphoma
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a new patent protecting the...
Nov 08, 2018 07:30 am ET
Kura Oncology Adds Commercial Veteran Mary Szela to Board of Directors
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced the appointment of commercial veteran Mary Szela to its board of directors. Throughout...
Nov 06, 2018 07:30 am ET
Kura Oncology to Participate in Two Upcoming Investor Conferences
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to...
Nov 05, 2018 04:05 pm ET
Kura Oncology Reports Third Quarter 2018 Financial Results and Provides Corporate Update
Kura Oncology, Inc., (Nasdaq: KURA) a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today reported third quarter 2018 financial results and provided a corporate update. “We are very...
Nov 05, 2018 07:30 am ET
Kura Oncology Initiates Registration-Directed Trial of Tipifarnib in HRAS Mutant Head and Neck Squamous Cell Carcinomas
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced the initiation of its global, multi-center, registration-directed trial of tipifarnib in...
Nov 01, 2018 09:00 am ET
Kura Oncology Announces Upcoming Presentations at ASH Annual Meeting
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that two abstracts related to the company’s lead product candidate, tipifarnib, have been...
Oct 29, 2018 07:30 am ET
Kura Oncology to Report Third Quarter 2018 Financial Results
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that it will report third quarter 2018 financial results after the close of U.S....
Oct 23, 2018 09:15 am ET
Factors of Influence in 2018, Key Indicators and Opportunity within Dropbox, Kura Oncology, DHT, Wayfair, US Foods Holding, and InflaRx N.V — New Research Emphasizes Economic Growth
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Dropbox, Inc. (NASDAQ:DBX), Kura Oncology, Inc. (NASDAQ:KURA), DHT...
Oct 22, 2018 08:45 am ET
Kura Oncology Presents Update on Positive Phase 2 Trial of Tipifarnib in HRAS Mutant HNSCC and Preliminary Results in HRAS Mutant SCC
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today reported updated preliminary results from a Phase 2 clinical trial of its lead product candidate,...
Sep 26, 2018 04:05 pm ET
Kura Oncology to Present at Leerink Partners Rare Disease & Oncology Roundtable
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that Troy Wilson, Ph.D., J.D., Kura’s President and Chief Executive Officer, is scheduled...
Aug 30, 2018 07:30 am ET
Kura Oncology to Present at H.C. Wainwright Global Investment Conference
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced its participation at the H.C. Wainwright 20th Annual Global Investment Conference. Troy...
Aug 07, 2018 04:05 pm ET
Kura Oncology to Present at 2018 Wedbush PacGrow Healthcare Conference
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced its participation at the 2018 Wedbush PacGrow Healthcare Conference. Troy Wilson, Ph.D.,...
Aug 06, 2018 04:05 pm ET
Kura Oncology Reports Second Quarter 2018 Financial Results and Provides Corporate Update
Kura Oncology, Inc., (Nasdaq: KURA) a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today reported second quarter 2018 financial results and provided a corporate update. “I am very...
Jul 31, 2018 07:30 am ET
Kura Oncology Appoints Marc Grasso, M.D., as Chief Financial Officer and Chief Business Officer
Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced the appointment of Marc Grasso, M.D., as Chief Financial Officer and Chief Business...
Jul 30, 2018 04:05 pm ET
Kura Oncology to Report Second Quarter 2018 Financial Results
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that it will report second quarter 2018 financial results after the close of U.S....
Jul 02, 2018 04:30 pm ET
Kura Oncology Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares
Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced the closing of its previously announced underwritten public offering of common stock,...
Jun 28, 2018 07:30 am ET
Kura Oncology Announces Pricing of $67 Million Public Offering of Common Stock
Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced the pricing of an underwritten public offering of 4,000,000 shares of its common stock at...
Jun 27, 2018 04:01 pm ET
Kura Oncology Announces Commencement of Public Offering of Common Stock
Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that it has commenced an underwritten public offering, subject to market and other...
Jun 20, 2018 07:30 am ET
Kura Oncology Appoints Chief Operating Officer, Expands Clinical Development Team as Company Prepares for First Registration-Directed Trial
Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced the appointment of John Farnam to the newly created position of Chief Operating Officer,...
Jun 14, 2018 07:30 am ET
Kura Oncology to Present at JMP Securities Life Sciences Conference
Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that Troy Wilson, Ph.D., J.D., Kura’s President and Chief Executive Officer, is scheduled...
May 22, 2018 07:00 am ET
OncoDNA announces screening collaboration with Kura Oncology
OncoDNA (“OncoDNA or “the Company”), the healthcare technology company making precision medicine a reality, is pleased to announce that it has signed a screening agreement with Kura Oncology, Inc. (“Kura”) (NASDAQ:KURA). Under the agreement,...
May 08, 2018 04:05 pm ET
Kura Oncology Reports First Quarter 2018 Financial Results and Provides Corporate Update
Kura Oncology, Inc., (Nasdaq:KURA) a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today reported first quarter 2018 financial results and provided a corporate update. “I am very pleased...
May 03, 2018 07:30 am ET
Kura Oncology to Present at Deutsche Bank 43rd Annual Health Care Conference
Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced its participation in the Deutsche Bank 43rd Annual Health Care Conference. Troy Wilson,...
May 02, 2018 07:30 am ET
Kura Oncology Announces New Patent for Tipifarnib in Hematologic Malignancies
Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a new patent protecting the...
May 01, 2018 07:30 am ET
Kura Oncology to Report First Quarter 2018 Financial Results
SAN DIEGO, May 01, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that it will report first quarter 2018 financial results after the...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.